

Maria G Tektonidou

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8252688/maria-g-tektionidou-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182
papers

9,059
citations

42
h-index

93
g-index

206
ext. papers

11,901
ext. citations

5.6
avg, IF

6.08
L-index

#	Paper	IF	Citations
182	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
181	Comparison of evidence of treatment effects in randomized and nonrandomized studies. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 821-30	27.4	567
180	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
179	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2074-82	2.4	462
178	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 476-485	2.4	375
177	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1011-8	2.4	369
176	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. <i>Lupus</i> , 2011 , 20, 206-18	2.6	351
175	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
174	Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2083-9	2.4	335
173	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1296-1304	2.4	312
172	Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6151-6157	15.9	307
171	14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. <i>Autoimmunity Reviews</i> , 2014 , 13, 685-96	13.6	248
170	Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2009 , 61, 29-36		227
169	Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1432-41	9.5	183
168	Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2569-79		168
167	Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. <i>American Journal of Medicine</i> , 2007 , 120, 636-42	2.4	141
166	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015 , 14, 401-14	13.6	136

165	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014 , 13, 281-91	13.6	112
164	Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003 , 48, 732-6		110
163	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 526-31	2.4	104
162	Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. <i>Arthritis Care and Research</i> , 2015 , 67, 1078-85	4.7	98
161	Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. <i>Archives of Internal Medicine</i> , 2006 , 166, 2278-84		92
160	Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2009-2016	2.4	90
159	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015 , 14, 192-200	13.6	86
158	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , 2015 , 2, e000123	4.6	86
157	Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1159-61	2.4	80
156	Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. <i>British Journal of Rheumatology</i> , 2003 , 42, 645-51		79
155	Methodological quality of studies of end-stage renal disease risks in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2014 , 16, A47	5.7	78
154	Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. <i>Clinical Reviews in Allergy and Immunology</i> , 2009 , 36, 131-40	12.3	74
153	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. <i>Lupus</i> , 2011 , 20, 165-73	2.6	72
152	Microvascular abnormalities in Sjögrenß syndrome: nailfold capillaroscopy. <i>Rheumatology</i> , 1999 , 38, 826-30	3.9	71
151	Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. <i>Autoimmunity Reviews</i> , 2017 , 16, 308-312	13.6	63
150	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. <i>Lupus</i> , 2011 , 20, 174-81	2.6	61
149	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014 , 53, 275-84	3.9	57
148	Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 60-2	4.1	53

147	Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008 , 27, 795-7	3.9	52
146	Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. <i>Clinical Rheumatology</i> , 2007 , 26, 258-60	3.9	51
145	Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. <i>Journal of Rheumatology</i> , 2008 , 35, 1983-8	4.1	48
144	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1079-1089	2.4	45
143	Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 43-8	2.4	45
142	Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. <i>Emerging Infectious Diseases</i> , 2009 , 15, 956-9	10.2	44
141	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. <i>Rheumatology International</i> , 2017 , 37, 1249-1255	3.6	42
140	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018 , 4, e000793	3.9	42
139	Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey. <i>Arthritis Care and Research</i> , 2011 , 63, 247-60	4.7	41
138	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , 2018 , 57, 1264-1270	3.9	40
137	Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 467-474	5.3	39
136	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. <i>Lupus</i> , 2018 , 27, 399-406	2.6	39
135	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-468	5.3	38
134	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. <i>Autoimmunity Reviews</i> , 2020 , 19, 102491	13.6	38
133	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>RMD Open</i> , 2019 , 5, e000924	5.9	35
132	Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. <i>International Journal of Cardiology</i> , 2017 , 236, 151-156	3.2	34
131	Suicidal ideation among adults with arthritis: prevalence and subgroups at highest risk. Data from the 2007-2008 National Health and Nutrition Examination Survey. <i>Arthritis Care and Research</i> , 2011 , 63, 1322-33	4.7	34
130	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 1924-30	4.3	33

129	B-cell activating factor and related genetic variants in lupus related atherosclerosis. <i>Journal of Autoimmunity</i> , 2018 , 92, 87-92	15.5	32
128	Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. <i>Clinical Rheumatology</i> , 2008 , 27, 541-2	3.9	30
127	Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2680-2685	9.5	30
126	Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	30
125	Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. <i>Rheumatology</i> , 2013 , 52, 448-54.9	3.9	29
124	Validation of new biomarkers in systemic autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 708-17	8.1	29
123	Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. <i>Frontiers in Immunology</i> , 2018 , 9, 1181	8.4	28
122	Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. <i>Lupus</i> , 2018 , 27, 564-571	2.6	27
121	Emerging Therapies in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2016 , 18, 22	4.9	27
120	Immunologic factors in the pathogenesis of osteonecrosis. <i>Orthopedic Clinics of North America</i> , 2004 , 35, 259-63, vii	3.5	27
119	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27
118	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019 , 38, 125-132	3.9	26
117	Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. <i>Journal of Clinical Immunology</i> , 1998 , 18, 380-91	5.7	26
116	Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 558-65	5.3	25
115	Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020 , 106, 102329	15.5	24
114	Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. <i>Autoimmunity Reviews</i> , 2018 , 17, 816-820	13.6	23
113	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
112	Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. <i>Frontiers in Immunology</i> , 2019 , 10, 487	8.4	22

111	Identification and treatment of APS renal involvement. <i>Lupus</i> , 2014 , 23, 1276-8	2.6	22
110	Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. <i>Rheumatology</i> , 2020 , 59, v29-v38	3.9	21
109	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018 , 4, e000785	5.9	21
108	Brief Report: Drug-Free Long-Term Remission in Severe Behçet Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2380-2385	9.5	20
107	Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 883-889	5.3	17
106	Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. <i>European Journal of Clinical Investigation</i> , 2000 , 30, 646-52	4.6	17
105	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report 2017 , 317-338		16
104	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
103	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 267	5.7	16
102	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019 , 126, 656-661	3.7	16
101	Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 611-6	5.3	15
100	Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. <i>Journal of Autoimmunity</i> , 2019 , 104, 102311	15.5	14
99	Reiter syndrome during intravesical BCG therapy for bladder carcinoma. <i>Clinical Rheumatology</i> , 2007 , 26, 1368-9	3.9	14
98	Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 579-585	2.2	14
97	Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. <i>Rheumatology</i> , 2018 , 57, 2158-2166	3.9	13
96	Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis		
95	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
94	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1490-1504	4.7	13

93	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019 , 175, 32-36	8.2	12
92	Does seronegative obstetric APS exist? "pro" and "cons". <i>Autoimmunity Reviews</i> , 2019 , 18, 102407	13.6	12
91	Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2010 , 12, R179	5.7	12
90	Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 304-307	2.4	12
89	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776	2.6	12
88	The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial. <i>RMD Open</i> , 2020 , 6,	5.9	11
87	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	11
86	Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2020 , 11, 8	3.7	10
85	Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320906650	3.9	10
84	HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups. <i>Human Immunology</i> , 1999 , 60, 1274-80	2.3	10
83	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
82	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. <i>Rheumatology International</i> , 2021 , 42, 31	3.6	9
81	Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20976975	3.8	9
80	Joint microwave radiometry for inflammatory arthritis assessment. <i>Rheumatology</i> , 2020 , 59, 839-844	3.9	9
79	Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
78	Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations. <i>European Journal of Echocardiography</i> , 2010 , 11, 184-5		8
77	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2020 , 22, 51	4.9	8
76	Independent association of low IFN γ gene expression and type I IFN score/IFN γ ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. <i>Clinical Immunology</i> , 2019 , 209, 108265	9	7

75	Appropriate screening for leishmaniasis before immunosuppressive treatments. <i>Emerging Infectious Diseases</i> , 2009 , 15, 1706; author reply 1706-7	10.2	7
74	Osteoarticular manifestations of antiphospholipid syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 523-35	2.4	7
73	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021 , 60, 170-178	3.9	7
72	Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA. <i>Rheumatology</i> , 2019 , 58, 1794-1801	3.9	6
71	Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance. <i>Clinical Infectious Diseases</i> , 2015 , 60, 868-74	11.6	6
70	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
69	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018 , 29, 27-37	1.4	6
68	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 288-294	1.4	6
67	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 2021 , 229, 108765	9	6
66	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases.. <i>RMD Open</i> , 2022 , 8,	5.9	6
65	Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis.. <i>Journal of Autoimmunity</i> , 2022 , 128, 102813	15.5	6
64	Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-sectional Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
63	All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. <i>RMD Open</i> , 2021 , 7,	5.9	5
62	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. <i>Rheumatology International</i> , 2021 , 41, 895-902	3.6	5
61	Retinal vascular calibers in contemporary patients with chronic systemic inflammatory diseases: The Greek REtinal Microcirculation (GREM) study. <i>Artery Research</i> , 2017 , 18, 1	2.2	4
60	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
59	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome 2017 , 223-233		4
58	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome 2017 , 247-266		4

57	Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 346-352	3.9	4
56	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X2093713	3.8	4
55	Growth Differentiation Factor 15 (GDF-15) as potential cardiovascular risk biomarker in Antiphospholipid Syndrome. <i>Rheumatology</i> , 2021 ,	3.9	4
54	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021 , 7,	5.9	4
53	Vasculitis beyond aortitis in IgG4-related disease (IgG4-RD): case report and review of the literature. <i>Clinical Rheumatology</i> , 2021 , 40, 1167-1173	3.9	4
52	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
51	B-cell oligoclonal expansions in renal tissue of patients with immune-mediated glomerular disease. <i>Clinical Immunology</i> , 2020 , 217, 108488	9	3
50	Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report. <i>Journal of Medical Case Reports</i> , 2011 , 5, 563	1.2	3
49	MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. <i>Lupus</i> , 2010 , 19, 1243-5	2.6	3
48	Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus. <i>Lupus</i> , 2003 , 12, 723-4	2.6	3
47	Myocardial Involvement in Rheumatic Disorders. <i>Current Heart Failure Reports</i> , 2020 , 17, 171-180	2.8	3
46	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021 , 23, 45	4.9	3
45	Psoriasis as an adverse reaction to biologic agents beyond anti-TNF- α therapy. <i>European Journal of Dermatology</i> , 2021 , 31, 307-317	0.8	3
44	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	3
43	JAK inhibitors: promising for a wider spectrum of autoimmune diseases?. <i>Lancet, The</i> , 2019 , 394, 2047-2048	4.8	3
42	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).. <i>Lupus</i> , 2021 , 9612033211062523	2.6	3
41	Reply. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1705	9.5	2
40	Presence of other autoimmune diseases in subjects with autoimmune thyroid disease. <i>American Journal of Medicine</i> , 2010 , 123, e23; author reply e25	2.4	2

39	Response to: Correspondence on EULAR recommendations for the management of antiphospholipid syndrome in adults by Zhou. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
38	Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. <i>RMD Open</i> , 2020 , 6,	5.9	2
37	Adrenocortical dysfunction in rheumatoid arthritis: Narrative review and future directions. <i>European Journal of Clinical Investigation</i> , 2021 , e13635	4.6	2
36	Clinical value of amyloid-beta1-40 as a marker of thrombo-inflammation in antiphospholipid syndrome. <i>Rheumatology</i> , 2021 , 60, 1669-1675	3.9	2
35	Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis. <i>Rheumatology International</i> , 2020 , 40, 1361-1368	3.6	1
34	Infections and Autoimmune Renal Diseases 2015 , 929-942		1
33	Antiphospholipid syndrome-associated nephropathy in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2012 , 7, 131-134	1.5	1
32	Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3-year prospective study. <i>Rheumatology</i> , 2021 ,	3.9	1
31	Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome. <i>Mediterranean Journal of Rheumatology</i> , 2018 , 29, 99-102	1.4	1
30	Task Force Report on Non-criteria Manifestations: Nephropathy 2012 , 207-221		1
29	Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20949088	3.8	1
28	Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2020 , 10, 16648	4.9	1
27	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria-documenting progress in lupus. <i>Rheumatology</i> , 2021 , 60, 2976-2978	3.9	1
26	Response to: Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled	2.4	1
25	Guideline: EULAR provided recommendations for thrombotic and obstetric antiphospholipid syndrome. <i>Annals of Internal Medicine</i> , 2019 , 171, JC26	8	1
24	Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study		1
23	Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
22	An Update on Antiphospholipid Syndrome.. <i>Current Rheumatology Reports</i> , 2022 , 23, 84	4.9	1

21	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation.. <i>Clinical and Experimental Rheumatology</i> , 2022 , 40 Suppl 134, 93-102	2.2	1
20	Alterations in cortisol and interleukin-6 secretion in patients with COVID-19 suggestive of neuroendocrine-immune adaptations.. <i>Endocrine</i> , 2022 , 75, 317	4	0
19	The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the PICO-UPP study. <i>Quality of Life Research</i> , 2021 , 1	3.7	0
18	Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2021 , 125, 102755	15.5	0
17	Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments. <i>Emerging Infectious Diseases</i> , 2009 , 15, 1706b-1707	10.2	0
16	Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin. <i>Clinical Rheumatology</i> , 2021 , 40, 2559-2568	3.9	0
15	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 2223-2230	3.9	0
14	Impaired hand function and performance in activities of daily living in systemic lupus erythematosus, even in patients achieving lupus low disease activity state (LLDAS). <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab029	1.1	0
13	Response to: Correspondence on EULAR recommendations for the management of antiphospholipid syndrome in adults by Gao and Qin. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	0
12	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 29-33	2.2	0
11	Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015. <i>Journal of Rheumatology</i> , 2017 , 44, 626-630	4.1	
10	Measures of psychological distress in patients with arthritis: comment on the article by Fuller-Thomson and Shaked. <i>Arthritis Care and Research</i> , 2010 , 62, 140-1; author reply 141-2	4.7	
9	Osteoarticular Manifestations of Antiphospholipid Syndrome 2006 , 127-139		
8	Antiphospholipid syndrome nephropathy in antiphospholipid antibody-positive patients with systemic lupus erythematosus: comment on the article by Tektonidou et al. <i>Arthritis and Rheumatism</i> , 2005 , 52, 988-9; author reply 989-90		
7	A case with epilepsy, cognitive impairment, renal microangiopathy and high titres of anticentromere and anticardiolipin antibodies. <i>Lupus</i> , 2005 , 14, 625-8	2.6	
6	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome 2012 , 167-179		
5	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. <i>Israel Medical Association Journal</i> , 2019 , 21, 292-297	0.9	
4	Mechanics of early ventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 119, 57-62	2.2	

- 3 Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 125, 29-39 2.2
- 2 Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 131, 29-33 2.2
- 1 New Insights Into an Overlooked Entity: Long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort.. *Frontiers in Medicine*, **2022**, 9, 809533 4.9